Objectives: This study aimed to evaluate the immuno-prophylactic and -therapeutic effect of p110d-specific pharmacological inhibitors (CAL-101 and IC87114), either alone or in combination with amphotericin B, against experimental cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL).
Introduction
Leishmaniasis is a vector-borne neglected tropical disease caused by an intracellular protozoan of the Leishmania genus. The symptoms range from self-healing skin ulcers in cutaneous leishmaniasis (CL) to weight loss, hepatomegaly and splenomegaly in visceral leishmaniasis (VL), which is a severe, deadly disease. 1 According to WHO, $0.7-1.3 million cases of CL and 200 000-400 000 cases of VL occur annually worldwide and $50 000 VL patients die from the disease every year. 2 The current drugs used for treatment of Leishmania infections are hindered by several problems, which include prolonged duration of treatment, toxicity, high costs and disease relapse. 3 In addition, the emergence of resistance to anti-leishmanial drugs suggests that the currently used monotherapy needs to be reviewed and possibly replaced with multidrug/combination therapies. VL in HIV-infected individuals is associated with higher initial leishmaniasis treatment failure, relapse and mortality rates. 4 Therefore, there is an urgent need to identify new drugs and treatment regimens.
Effective immunity against leishmaniasis is dependent on the development of a type-1 immune response that leads to the production of macrophage-activating cytokines, including IFN-c and TNF. In contrast, susceptibility is usually linked to the production of macrophage-deactivating cytokines, including IL-10. 5 Reports suggest that regulatory T cells (Tregs) 6, 7 and B cells 8, 9 also play a critical role in determining the outcome of Leishmania infection in both mice 6, 9 and humans. 7 Recently, we showed that mice with an inactivating knock-in mutation in the p110d subunit of the phosphatidylinositol 3 kinases (PI3K, termed p110d D910A mice) are hyper-resistant to both experimental CL and VL caused by Leishmania major 10 and Leishmania donovani, 11 respectively. This V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com resistance was in part, due to impaired expansion of Tregs in p110d D910A mice. 10, 11 Given the dramatic hyper-resistance observed in p110d D910A mice infected with L. donovani 11 and L. major, 10 we speculated that the use of highly specific pharmacological inhibitors of p110d may be beneficial in the treatment of experimental CL and VL by modulating the host immune response. We also predicted that the immunomodulatory effects of the inhibitors could act synergistically and allow the use of a lower dose of amphotericin B (a conventional leishmaniasis therapy), thereby significantly reducing the duration of the treatment regimen and drug toxicity, leading to improved drug efficacy.
Among the different categories of PI3K inhibitors developed to date, 12 IC87114 and CAL-101, which are p110d-specific pharmacological inhibitors, have received wide attention and CAL-101 has recently been approved for treatment of different B cell malignancies. [13] [14] [15] Here, we demonstrate for the first time that prophylactic and therapeutic administration of IC87114 and CAL-101 reduces lesion size (CL) and parasite burdens (VL and CL) at the infection sites and visceral organs. We further show that as in infected p110d D910A mice, CAL-101 treatment significantly reduced B cell and Treg numbers and the percentage of IFN-c-producing CD4þ T cells without affecting macrophage infectivity by the parasites. Importantly, combined low-dose CAL-101 and amphotericin B therapy leads to complete parasite clearance in mice infected with L. donovani. These observations have direct implications for immunomodulation and immunotherapy of both CL and VL.
Materials and methods

Ethics
The University of Manitoba Animal Use Ethics Committee approved all studies involving animals, including infection, humane endpoints, euthanasia and collection of samples (Protocol Number 12-072) according to the guidelines stipulated by the Canadian Council for Animal Care.
Mice, infection and parasite quantification
Female BALB/c mice were bred and maintained at the Central Animal Care Services (CACS) under specific pathogen-free conditions. Mice aged 6-8 weeks and weighing 20 g maintained on a 12 h light/dark cycle with free access to food and water, were infected intravenously with 5 Â 10 7 7 day stationary-phase L. donovani (strain LV9) or 10 4 L. major (strain MHOM/80/Friedlin) promastigotes grown in complete M199 insect culture medium (Invitrogen, NY, USA). 16 At different times post-infection, mice were sacrificed and parasite burden in the liver, spleen and footpad was determined as previously described. 11 Lesion size was also measured in L. major-infected footpads using callipers.
Prophylactic, therapeutic and combination therapy with p110d pharmacological inhibitors
For prophylactic treatment, mice were administered CAL-101 (idelalisib/GS-1101/Zydelig 17 ) (0.05 mg/mouse) or IC87114 (0.5 mg/mouse) (both from Selleck Chemicals LLC, TX, USA), intraperitoneally or orally 18 twice a day, 24 h prior to infection. Intraperitoneal or oral injection of CAL-101 and/or IC87114 was continued every 12 h for 2 weeks. For therapeutic treatment, mice were infected with L. donovani promastigotes and after 1 week or 2 weeks CAL-101 was administered intraperitoneally every 12 h for an additional period of 2 weeks. For combination therapy, mice were infected with L. donovani promastigotes and after 2 weeks were treated intraperitoneally with CAL-101 (0.05 mg/mouse), amphotericin B (Fungizone, Bristol-Myers Squibb, Montreal, Canada; 0.1 mg/kg), combined CAL-101 and amphotericin B or PBS once daily for 5 consecutive days and sacrificed at 1 week or 3 weeks after last treatment. Additionally, 1 week after the last combined CAL-101 and amphotericin B treatment, some mice were treated with anti-IFN-c MAb (1 mg/mouse intraperitoneally) as previously described. 19, 20 Mice were sacrificed 2 weeks post-anti-IFN-c mAb administration. In all experiments, control mice received DMSO in PBS (vehicle control).
Assessment of B cells, Tregs and cytokine production
At different times, mice were sacrificed and the spleens, livers and lymph nodes were collected. The spleens and lymph nodes were made into single-cell suspensions in complete DMEM (DMEM supplemented with 10% heat-inactivated FBS, 2 mM glutamine, 100 U/mL penicillin and 100 lg/mL streptomycin). The livers were digested with collagenase D (0.125 mg/mL) for 30 min at 37 C and homogenized in complete DMEM, and liver lymphocytes were separated using Percoll gradient centrifugation as previously described. 11, 21 Cells were counted and directly stained ex vivo for CD3, CD4, CD25 and B220 (extracellular staining) and Foxp3 (intracellular staining using a BD Biosciences Foxp3 Staining Kit) expression. In some experiments, liver, spleen and lymph node lymphocytes were stimulated with 50 ng/mL phorbol 12-myristate 13-acetate, 500 ng/mL ionomycin and 0.1 mg/mL brefeldin A for 4 h, fixed, surface-stained for CD3 and CD4, and stained intracellularly for IFN-c. 10, 11 Samples were acquired on a FACSCanto II cytometer (BD Bioscience, San Diego, CA, USA) and analysed using FlowJo software (Tree Star, Ashland, OR, USA). Spleen, liver and lymph node cells were also resuspended at 4 Â 10 6 /mL in complete DMEM, plated at 1 mL/well in 24-well tissue culture plates, stimulated with freeze-thawed L. donovani (0.01 mg/mL) or soluble Leishmania antigen (0.005 mg/mL) and cultured at 37 C. After 3 days, the supernatant fluids were collected and assayed for cytokines [IFN-c, IL-10, IL-6, IL-4 and keratinocyte chemoattractant (KC)/human growth-related oncogene (GRO)] using a V-PLEX Plus Proinflammatory Panel 1 (mouse) Kit (Meso Scale Discovery, MD, USA) or ELISA according to the manufacturer-suggested protocols.
Measurement of serum antibody levels
At sacrifice, serum was obtained from infected and treated (CAL-101 prophylactic treatment) mice and used to determine the Leishmania-specific antibody titres (IgG, IgM, IgG1 and IgG2a) by ELISA as previously described. 22 Briefly, high protein binding ELISA plates were coated with freeze-thawed L. donovani (5 Â 10 7 parasites/ml, 10 lL/well) overnight at 4 C, incubated with blocking buffer (2% BSA) for 2 h at 37 C and then washed. Serum samples and standards were serially diluted, added to the wells and incubated at 37 C for 2 h. Plates were washed and bound antibody levels were detected at 405 nm using biotinylated antimouse IgG, IgM, IgG1 or IgG2a (Southern Biotech). 
Assessment of CAL-101-and amphotericin-B-induced toxicity in macrophages in vitro
Retrovirus-immortalized bone marrow-derived macrophage (BMDM) cells (ANA-1 cells) 23 were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 U/mL penicillin and 0.1 mg/mL streptomycin at 37 C for Khadem et al.
3 days. The cells were then treated with either CAL-101 or amphotericin B (ranging from 10 nM to 20 lM) for 24 h and assessed for apoptosis by flow cytometry using an Annexin V FITC Apoptosis Detection Kit according to the manufacturer-suggested protocols. 24 In vitro infection of macrophages in the presence of P110d pharmacological inhibitors ANA-1 cells were grown in complete RPMI medium 23 and infected with 7 day stationary-phase L. donovani or L. major promastigotes at a cell-toparasite ratio of 1:5 for 5 h. Free parasites were washed away and infected macrophages were further cultured for 24 and 72 h at 37 C in the presence of IC87114 (0, 1 and 10 lM) or CAL-101 (0, 0.1 and 1 lM) or amphotericin B (10 nM). [25] [26] [27] At the end of the cultures, the level of infection was determined by counting haematoxylin/eosin-stained cytospin preparations under a Zeiss Primo Star (Zeiss, Melville, NY, USA) light microscope with a Â100 (oil) objective.
Statistical analysis
Student's t-test was used to compare the mean and SEM between two groups and non-parametric one-way or two-way analysis of variance (ANOVA) was used to compare the mean and SD of more than two groups using the Prism program (GraphPad Software Inc., CA, USA). Tukey's or Bonferroni post tests were used where there were significant differences in ANOVA. Error bars indicate 6SEM and differences were considered significant when P < 0.05.
Results
Prophylactic administration of p110d pharmacological inhibitors confers protection against VL and CL
We previously showed that mice with an inactivating knock-in mutation in the p110d isoform of PI3K (p110d D910A ) are hyper-resistant to L. major 10, 28 and L. donovani. 11, 16 Because this resistance is independent of parasite species and genetic background, we wanted to assess whether targeting the PI3K signalling pathway with p110d pharmacological inhibitors may be useful for treatment of both CL and VL. We administered CAL-101 or IC87114 to mice intraperitoneally 18 or orally (CAL-101 only) twice a day, 24 h prior to intravenous or subcutaneous infection with L. donovani or L. major. Prophylactic administration of CAL-101 resulted in significantly (P < 0.01) lower parasite burden in the spleen ( Figure 1a ) and liver (Figure 1b ) of L. donovani-infected mice and footpad (Figure 1c ) of L. major-infected mice. The reduction in parasite burden in the footpads was also associated with significant (P < 0.01) reduction in lesion size of L. major-infected mice (Figure 1d ). Interestingly, there was no significant difference in parasite burden in the spleens and livers of L. donovani-infected p110d D910A mice either treated or not treated with CAL-101, suggesting that intact p110d signalling is critical for the effects observed in treated mice (Figure 1a and b) . Similar results were observed in mice treated with IC87114 ( Figure S1a , b and c, available as Supplementary data at JAC Online). Thus, as observed in mice with inactive knock-in mutation, pharmacological inhibition of p110d isoform of PI3K leads to enhanced resistance to experimental visceral and cutaneous leishmaniasis.
Prophylactic administration of p110d pharmacological inhibitors alters host immune response to Leishmania
Enhanced resistance of p110d D910A mice to experimental leishmaniasis is associated with reduced immune activation and cytokine responses.
10,11 Therefore, we assessed the quality of immune response in mice treated with CAL-101 in order to determine whether pharmacological inhibitors also affect the immune response in a similar manner. At sacrifice, liver, spleen or lymph node lymphocytes were assessed directly ex vivo for the numbers of Treatment with CAL-101 leads to reduction in parasite burden in mice with established disease Treatment of leishmaniasis is challenging due to prolonged duration of treatment and the fact that most of the current drugs are toxic and have numerous side effects. 30 Because CAL-101 (idelalisib) has recently been approved by the FDA for use in patients with different B cell malignancies, 13, 15, 31 and given its beneficial prophylactic effects against leishmaniasis (Figure 1 ), we assessed its therapeutic potential for treatment of established experimental VL.
Mice were infected with L. donovani and after 1 week or 2 weeks were treated with CAL-101 every 12 h for a period of 2 weeks. CAL-101 treatment initiated 1 week or 2 weeks after L. donovani infection resulted in significantly (P < 0.05) lower parasite burden in the spleens ( Figure S3a Figure S3i , j, k and l) cells from L. donovani-infected mice. These findings are consistent with our previous findings indicating that resistance to VL and CL observed in p110d D910A mice is due to reduced Treg levels and that reduced production of IFN-c does not affect the outcome of disease. They further show a beneficial therapeutic effect of targeting this pathway in treatment of VL.
Combined CAL-101 and amphotericin B therapy cures experimental VL
The growing resistance to anti-leishmanial drugs and high relapse rates of VL suggest that the currently used monotherapy needs to be reviewed and possibly replaced with multidrug combination and/or immunotherapy. Therefore, we determined whether treatment of infected mice with low-dose CAL-101 and amphotericin B, a commonly used anti-Leishmania compound, would lead to better protection that might be associated with minimal toxicity. We treated different groups of L. donovani-infected mice with CAL-101 either alone or in combination with amphotericin B (0.01 mg/kg). Remarkably, combination therapy with CAL-101 and amphotericin B (1 week or 3 weeks post-therapy) led to complete clearance of parasites both in the spleen ( Figure S4a Khadem et al.
observations suggest that the protection in CAL-101 and amphotericin-B-treated mice may be IFN-c independent and that treated mice were cured of infection.
P110d pharmacological inhibitors do not directly inhibit Leishmania growth in axenic cultures or in infected macrophages
Because L. donovani is known to activate the PI3K/AKT pathway in macrophages, 32 we assessed whether p110d pharmacological inhibitors influence Leishmania growth directly (in axenic cultures) or indirectly (by affecting macrophage activation), leading to parasite death. Therefore, we tested the ability of CAL-101 and IC87114 to directly inhibit proliferation of L. major and L. donovani promastigotes in axenic cultures. The results were compared with Leishmania growth in the presence of amphotericin B. Parasite growth was monitored every day by counting the number of parasites in cultures over 7 days. The results shown in Figure 6(a and b) indicate that the in vitro growth and proliferation of these parasites were not affected by any concentration of CAL-101 tested. In contrast and consistent with previous reports, amphotericin B completely inhibited survival and proliferation (Figure 6a and b) . Additionally, whereas amphotericin B suppressed parasite proliferation in macrophages, CAL-101 did not affect either infectivity or parasite proliferation inside macrophages in vitro (Figure 6c and d) . Similar results were also obtained for IC87114 ( Figure S5a , b, c and d). We further compared the effects of various concentrations of CAL-101 and amphotericin B on macrophage (ANA-1 cells) apoptosis in order to determine their CC 50 . The data presented in Figure 6 (e and f) show that the CC 50 of CAL-101 and amphotericin B were 10 lM and 100 nM, respectively. Collectively, these results confirm that the in vivo beneficial effects of CAL-101 and IC87114 are not mediated by direct parasite killing but through their ability to modulate the host immune response to Leishmania.
Discussion
Leishmaniasis remains an important parasitic disease and is spreading to several non-endemic areas of the world. Importantly, drug resistance and increasing Leishmania/HIV coinfections, associated with high failure and relapse rates, pose significant challenges to monotherapy. [33] [34] [35] Moreover, the treatment of VL in CAL-101 confers protection against leishmaniasis JAC HIV-infected individuals with CD4þ T cell counts <200 cells/mm 3 required even higher doses. 36 Many of the frontline drugs for treating the disease, such as amphotericin B, liposomal amphotericin B and miltefosine, are associated with numerous side effects, including gastrointestinal intolerance and significant toxicity to the liver, kidneys and spleen. 37, 38 Therefore, there is urgent need for development of novel therapies, including immunotherapy.
We previously reported that mice with an inactive knock-in mutation in the p110d subunit of PI3K exhibit enhanced resistance to different experimental forms of leishmaniasis, including CL and VL. 10, 11 This resistance was independent of parasite species and mouse genetic background, 10, 11 suggesting that targeting this pathway could provide a novel therapeutic approach for treatment of leishmaniasis. Here, we have investigated whether treatment of Leishmania-infected mice with highly specific pharmacological inhibitors of p110d signalling could be beneficial in treating leishmaniasis.
Different categories of PI3K inhibitors, including pan-PI3K, dual-PI3K/mTOR and isoform-specific PI3K inhibitors, have been developed, but most of these have encountered problems as monotherapeutic agents in clinical trials due to limited efficacies and relatively high rates of adverse side effects. 12 Although IC87114 was the first p110d-specific inhibitor, 39, 40 and is still being used in research, 41, 42 it has a very high IC 50 (0.5 lM) compared with CAL-101, which has an IC 50 of 2.5 nM. [13] [14] [15] Therefore, CAL-101 has taken the lead over IC87114 in clinical trials and research applications and has shown great promise in the clinical management of conditions where PI3K inhibitions were thought to be beneficial. [13] [14] [15] We report here for the first time that both CAL-101 and IC87114, when used as prophylactic treatments, can reduce lesion or ELISA (i, j and k). Results are representative of two independent experiments (n ¼ 4 mice per group per experiment) with similar results. Error bars, 6SEM; *P < 0.05; **P < 0.01; ***P < 0.001.
size (CL) and parasite burdens in the footpads (CL), spleens and livers (VL) of Leishmania-infected mice. Also, we demonstrated that CAL-101 has therapeutic effects in VL, as treatment initiated as late as 2 weeks after infection causes a significant reduction in parasite numbers in both the spleens and livers of infected animals. Strikingly, we further demonstrated that combined low-dose CAL-101 and amphotericin B therapy has the ability to cause complete clearance of parasites in L. donovani-infected mice, demonstrating the potential benefits of this combination therapy in treatment of VL. This superior effect of CAL-101 and amphotericin B combination therapy offers the advantage of avoiding emergence of drug resistance Although single-or multiple-dose liposomal formulations of amphotericin B (Fungisome or AmBisome) have been reported to be effective for treatment of VL, prolonged treatment with amphotericin B is still the main treatment regimen in different parts of . CAL-101 therapy is effective against established L. donovani infection. BALB/c mice were infected intravenously with 5 Â 10 7 L. donovani promastigotes and after 2 weeks CAL-101 was administered intraperitoneally every 12 h for 2 weeks. At sacrifice, parasite burden in the spleen (a) and liver (b) was determined by limiting dilution assay. Spleen and liver lymphocytes were isolated, directly stained ex vivo and the percentages of CD25 þ Foxp3þ Tregs (c) were determined by flow cytometry by gating on live CD3 þ CD4þ cells. The percentages of IFN-c-producing CD4þ T cells (d) were also determined after stimulation with PMA, ionomycin and brefeldin A for 4 h after gating on live CD3þ cells. Spleen (e, f, g and h) and liver (i, j, k and l) lymphocytes were also cultured for 72 h in the presence of freeze-thawed L. donovani and the levels of cytokines (IFN-c, IL-10, IL-6 and KC/ GRO) in the culture supernatant fluids were determined by V-PLEX Meso Scale. Results are representative of two independent experiments (n ¼ 4 mice per group per experiment) with similar results. Error bars, 6SEM. *P < 0.05 and **P < 0.01.
CAL-101 confers protection against leishmaniasis JAC the world. For example, intravenous injections of amphotericin B (1 mg/kg every other day for 15 days and at 15 mg/kg over 30 days) have been reported in human studies. 43 An experimental mouse study found that effective treatment of two strains of Leishmania infantum required multiple injections of 0.5-0.8 mg/kg of amphotericin B on various days. 44 Here, we chose to use amphotericin B (Fungizone) at 0.1 mg/kg, 2 weeks after infection, in combination with CAL-101. The results obtained indicate that this combination therapy has the ability to cause complete clearance of parasites both in spleen and liver of L. donovani-infected animals, as checked at different timepoints after therapy. Furthermore, parasite load in these mice remained undetectable following administration of anti-IFN-c MAb, suggesting that combination therapy may have led to complete cure. Thus, CAL-101 and amphotericin B combination therapy dramatically reduced drug dose and duration of treatment, which could potentially reduce the associated toxicity and side effects of the drugs. The combination therapy may also be of particular benefit in the difficult-to-manage VL/HIV coinfection.
The very low IC 50 associated with CAL-101 allows the administration of relatively higher doses, leading to enhanced target and Liver Spleen Figure 5 . CAL-101 and amphotericin B combination therapy leads to complete parasite clearance in spleens and livers of L. donovani-infected mice. BALB/c mice were infected intravenously with 5 Â 10 7 L. donovani and, after 2 weeks, treated with CAL-101, amphotericin B or a combination of CAL-101 and amphotericin B once daily for 5 days. In addition, some mice treated with the combined CAL-101 and amphotericin B regimen were treated with anti-IFN-c mAb at 1 week after the last drug treatment and sacrificed after 2 weeks to determine parasite burden in the spleen (a) and liver (b). At sacrifice, spleen and liver lymphocytes were isolated and directly stained ex vivo to assess Foxp3 expression. The dot plot represents Foxp3þ Tregs previously gated on live CD4 þ CD25þ cells (c and d). Some cells were stimulated with PMA, ionomycin and brefeldin A for 4 h, and fixed and stained for intracellular IFN-c expression (e and f). Results are representative of two or three independent experiments (n ¼ 4 mice per group per experiment) with similar results. Error bars, 6SEM; *P < 0.05; **P < 0.01; ***P < 0.001. AMB, amphotericin B.
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pathway suppression and efficacy. 31, 45 Although in some limited cases CAL-101 has been associated with adverse side effects, such as hepatotoxicity, diarrhoea or colitis, and fatal and serious pneumonia or intestinal perforation, 46 ,47 the compound remains one of the safest PI3K inhibitors available for clinical practice. Here, we found that the IC 50 of CAL-101 (2.5 nM) is several orders of magnitude below the CC 50 (20 lM) , confirming that the compound can effectively kill the parasites without causing any adverse effects (e.g. apoptosis of the host cells). In contrast, the IC 50 of amphotericin B (100-700 nM 48 ) is equal to the CC 50 (100 nM) obtained here, suggesting that the drug would induce host cell apoptosis before killing parasites. This would account for the very high toxicity associated with the current dose of the drug used clinically. 43 Therefore, the very low concentrations of amphotericin B used in this study might have the ability to reduce drug-induced cytotoxicity in vivo.
We previously showed that enhanced resistance of p110d KI mice to CL and VL was paradoxically associated with impaired IFN-c response by immune cells in different organs of infected mice. 10, 11 We also showed that the deficiency of p110d signalling was associated with impaired Treg expansion and function in infected mice. Extensive analysis further revealed that the enhanced resistance in these mice was related to more efficient effector T cell responses in the face of impaired Treg activities and numbers. 11, 28 In line with this, we found here that treatment with CAL-101 was associated with significant CAL-101 confers protection against leishmaniasis JAC reduction in Treg numbers and cytokine responses in different organs of infected mice, suggesting that the beneficial effects of CAL-101 may be through its immunomodulatory effects. Interestingly, we also found that CAL-101 treatment resulted in reduced numbers of B cells and a concomitant decrease in serum levels of parasite-specific antibodies. This is consistent with previous reports showing that deficiency of p110d signalling results in defects in B cell receptor (BCR) signal and impaired antibody response. 29 It is conceivable that the impaired B cell response in these mice might contribute to the protection seen in CAL-101-treated mice, given that deficiency of B cells and/or impaired B cell responses have been linked to enhanced antiLeishmania immunity. 8, 9 In contrast, amphotericin B therapy alone increased IFN-c production and had no effect on Treg and B cell numbers in infected mice. This is consistent with reports that demonstrate amphotericin B interacts with both host and parasite membrane cholesterol, thereby effectively disrupting membrane integrity of the cells and parasites. 49 Hence, it could be considered that CAL-101 and amphotericin B combination therapy has two effects. One is targeting the p110d pathway, which leads to an effective immune response associated with leishmaniasis by reducing B cell and Treg numbers and function, and the other is by directly killing parasites, 50 thereby reducing their entry into macrophages. 49 Many factors, such as high-dose treatment regimens, toxicity, high costs, drug resistance and poor efficacy, are among the major challenges facing physicians treating patients with leishmaniasis. Therefore, it is critical that the current monotherapy options be enhanced or replaced by developing new drugs or utilizing multidrug/combination therapy. The combination therapy approach could lower the required drug doses and treatment regimens, reduce drug toxicity, improve drug efficacy, reduce emergence of drug-resistant strains and consequently reduce the chances of disease relapse. CAL-101 (idelalisib) has been approved by the FDA for treatment of several conditions, including B cell malignancies. [13] [14] [15] Our studies clearly demonstrate a novel therapeutic option for leishmaniasis based on CAL-101 monotherapy or CAL-101 and amphotericin B combination therapy. These observations have important and direct implications for immunotherapy and drug development against leishmaniasis.
